MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS
暂无分享,去创建一个
Junkai Chang | Weibo Xu | Xinyi Du | Junqing Hou | Wei-bo Xu | J. Hou | Junkai Chang | Xin-yi Du
[1] Timothy J Wilt,et al. Prevention and early detection of prostate cancer. , 2014, The Lancet. Oncology.
[2] A. De Siervi,et al. Implications of microRNA dysregulation in the development of prostate cancer. , 2017, Reproduction.
[3] Jie Li,et al. Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. , 2015, International journal of biological macromolecules.
[4] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[5] Channing J Der,et al. KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.
[6] N. Seki,et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer , 2011, British Journal of Cancer.
[7] N. Seki,et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. , 2012, European journal of cancer.
[8] S. Diederichs,et al. MALAT1 — a paradigm for long noncoding RNA function in cancer , 2013, Journal of Molecular Medicine.
[9] W. Catalona,et al. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). , 2009, Urologic oncology.
[10] Hongwei Liang,et al. miR‐1 suppresses the proliferation and promotes the apoptosis of esophageal carcinoma cells by targeting Src , 2017, Cancer medicine.
[11] M. Burchardt,et al. MicroRNA-1 properties in cancer regulatory networks and tumor biology. , 2016, Critical reviews in oncology/hematology.
[12] R. Stephens,et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer , 2011, Nucleic acids research.
[13] Q. Kan,et al. Regulation of microRNA-1 (miR-1) expression in human cancer. , 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.
[14] Cheng Huang,et al. Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease. , 2015, Current pharmaceutical design.
[15] Rui Yang,et al. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer , 2015, Tumor Biology.
[16] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[17] A. Stojadinovic,et al. Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer , 2014, Journal of Cancer.
[18] S. Dhanasekaran,et al. Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.
[19] Yan Zhang,et al. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. , 2016, Biochemical and biophysical research communications.
[20] Q. Lu,et al. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development , 2016, Tumor Biology.
[21] K. Takayama,et al. Long non‐coding RNAs and prostate cancer , 2017, Cancer science.
[22] Rosalie Nolley,et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.
[23] Xiaoqi Liu,et al. MicroRNAs in prostate cancer: Functional role as biomarkers. , 2017, Cancer letters.
[24] A. Partin,et al. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer , 2015, Prostate Cancer and Prostatic Disease.
[25] Artemis G Hatzigeorgiou,et al. Analyzing MiRNA-LncRNA Interactions. , 2016, Methods in molecular biology.
[26] S. Varambally,et al. Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance , 2017, Front. Oncol..
[27] M. Esteller,et al. lncRNAs and microRNAs with a role in cancer development. , 2016, Biochimica et biophysica acta.
[28] H. Miyake,et al. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches , 2013, International journal of urology : official journal of the Japanese Urological Association.
[29] W Abou-Kheir,et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms , 2013, Oncogene.
[30] J. Hou,et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. , 2013, The Journal of urology.
[31] Jingxuan Shi,et al. miR‐1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K‐ras in nasopharyngeal carcinoma , 2015, International journal of experimental pathology.
[32] F. Zhang,et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation , 2012, Medical Oncology.
[33] J. Mattick,et al. Non‐coding RNAs: regulators of disease , 2010, The Journal of pathology.
[34] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[35] Robert A. Weinberg,et al. Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.
[36] Jiří Drábek,et al. Clinical Relevance of KRAS in Human Cancers , 2010, Journal of biomedicine & biotechnology.
[37] Yong Wang,et al. Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells , 2017, Oncotarget.
[38] George A. Calin,et al. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer , 2017, International journal of molecular sciences.
[39] D. Bonci,et al. MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients' Samples , 2014, BioMed research international.
[40] P. Pandolfi,et al. The multilayered complexity of ceRNA crosstalk and competition , 2014, Nature.